A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Inhye E. Ahn(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Hannah Cormier(Harvard University), Yinglu Zhou(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Marykate Kilcommons(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890